Compare IPCA Labs with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs UNICHEM LAB - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS UNICHEM LAB IPCA LABS/
UNICHEM LAB
 
P/E (TTM) x 23.1 62.8 36.7% View Chart
P/BV x 4.5 0.7 662.9% View Chart
Dividend Yield % 0.1 2.1 5.1%  

Financials

 IPCA LABS   UNICHEM LAB
EQUITY SHARE DATA
    IPCA LABS
Mar-18
UNICHEM LAB
Mar-19
IPCA LABS/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs695292 238.2%   
Low Rs400182 219.8%   
Sales per share (Unadj.) Rs260.2167.7 155.2%  
Earnings per share (Unadj.) Rs19.0-3.6 -522.5%  
Cash flow per share (Unadj.) Rs33.15.9 556.3%  
Dividends per share (Unadj.) Rs1.004.00 25.0%  
Dividend yield (eoy) %0.21.7 10.8%  
Book value per share (Unadj.) Rs213.0372.3 57.2%  
Shares outstanding (eoy) m126.2070.38 179.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.11.4 148.9%   
Avg P/E ratio x28.9-65.3 -44.2%  
P/CF ratio (eoy) x16.639.9 41.5%  
Price / Book Value ratio x2.60.6 403.8%  
Dividend payout %5.3-110.2 -4.8%   
Avg Mkt Cap Rs m69,12016,680 414.4%   
No. of employees `00013.32.6 509.4%   
Total wages/salary Rs m7,3592,393 307.5%   
Avg. sales/employee Rs Th2,477.44,535.2 54.6%   
Avg. wages/employee Rs Th555.2919.8 60.4%   
Avg. net profit/employee Rs Th180.6-98.2 -183.9%   
INCOME DATA
Net Sales Rs m32,83611,801 278.3%  
Other income Rs m418984 42.5%   
Total revenues Rs m33,25412,785 260.1%   
Gross profit Rs m4,505-835 -539.6%  
Depreciation Rs m1,777674 263.8%   
Interest Rs m24075 319.4%   
Profit before tax Rs m2,905-600 -484.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m511-343 -148.8%   
Profit after tax Rs m2,394-256 -937.0%  
Gross profit margin %13.7-7.1 -193.9%  
Effective tax rate %17.657.3 30.7%   
Net profit margin %7.3-2.2 -336.7%  
BALANCE SHEET DATA
Current assets Rs m19,45520,384 95.4%   
Current liabilities Rs m10,0765,029 200.3%   
Net working cap to sales %28.6130.1 22.0%  
Current ratio x1.94.1 47.6%  
Inventory Days Days98105 93.4%  
Debtors Days Days67135 49.6%  
Net fixed assets Rs m20,2609,023 224.5%   
Share capital Rs m252141 179.3%   
"Free" reserves Rs m26,63326,058 102.2%   
Net worth Rs m26,88626,199 102.6%   
Long term debt Rs m2,3400-   
Total assets Rs m41,17331,496 130.7%  
Interest coverage x13.1-7.0 -187.8%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.4 212.9%   
Return on assets %6.4-0.6 -1,117.5%  
Return on equity %8.9-1.0 -913.0%  
Return on capital %10.8-2.0 -538.3%  
Exports to sales %47.669.4 68.7%   
Imports to sales %14.90-   
Exports (fob) Rs m15,6428,188 191.0%   
Imports (cif) Rs m4,884NA-   
Fx inflow Rs m15,6428,188 191.0%   
Fx outflow Rs m4,884596 819.4%   
Net fx Rs m10,7597,592 141.7%   
CASH FLOW
From Operations Rs m3,411-3,278 -104.1%  
From Investments Rs m-1,354-2,860 47.3%  
From Financial Activity Rs m-1,304-24 5,388.8%  
Net Cashflow Rs m753-4,690 -16.1%  

Share Holding

Indian Promoters % 45.9 50.1 91.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 15.1 75.5%  
FIIs % 25.3 3.0 843.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 31.7 54.9%  
Shareholders   36,892 20,176 182.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   DR. DATSONS LABS  STRIDES PHARMA SCIENCE  FDC LTD.  JUBILANT LIFE SCIENCES  BIOCON   

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

UNICHEM LAB Announces Quarterly Results (1QFY20); Net Profit Up 102.2% (Quarterly Result Update)

Jul 30, 2019 | Updated on Jul 30, 2019

For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

UNICHEM LAB 2018-19 Annual Report Analysis (Annual Result Update)

Jul 4, 2019 | Updated on Jul 4, 2019

Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

UNICHEM LAB Announces Quarterly Results (4QFY19); Net Profit Up 31.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - FDC LTD. COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS